BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Ra Pharma Crashed as Certain Patients Failed to Tolerate Switch From Alexion’s Soliris

  The patients who were transfusion dependent and switched from Soliris were forced to switch back to the Alexion drug.

  December 4, 2017

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Sanofi’s Bad End-of-the-Year Continues With Axing of Its C. Diff Drug

  Sanofi terminated an experimental Clostridium difficile vaccine after an Independent Data Monitoring Committee concluded the Phase III trial was unlikely to hit its endpoints.

  December 4, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Little Idorsia Scores $230M+ R&D Deal With Johnson & Johnson

  Today, Janssen Biotech announced it had exercised its option to enter into a collaboration deal with Idorsia to jointly develop and market aprocitentan and any derivative compounds.

  December 4, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Policy

  The Philippines Suspends Sanofi’s Dengue Vaccine After 730,000+ Children are Immunized

  Sanofi said the analysis showed more cases of severe disease could occur following vaccination in patients who had not been previously infected by the dengue virus.

  December 4, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Biotech Bay

  2 Bay Area Biotechs Expected to Grow 67% or Up Over the Next Five Years

  A look at two life science companies that are expected to grow more than 67 percent over the next five years.

  December 4, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Biotech Bay

  2 Biotechs Under $5 Bucks Investors Should Put on Their Watchlists

  Why investors may want to keep an eye on Idera Pharmaceuticals and Ekso Bionics.

  December 4, 2017

   · 

  1 min read
• 

  Drug Development

  Ultragenyx Stock Booms After Burosumab Continues to Impress in Phase III Study

  Shares of Ultragenyx are sharply climbing this morning after the company announced positive results from its Phase III study of burosumab in adults with XLH.

  December 4, 2017

   · 

  3 min read

   · 

  Alex Keown
• GenomicCare (Shanghai) Completes Series A; Brings Total Funding to $25M

  Although GenomiCare did not disclose the size of the A round, the company did say it has raised $25M since its inception in 2015.

  December 4, 2017

   · 

  1 min read
• Business

  12 Sigma, a US-China Startup, Raises $30M for AI-Imaging

  12 Sigma Technologies, a San Diego medical imaging firm founded by a team of Chinese scientists, raised $30M in a B round led by China VC firm SBCVC.

  December 4, 2017

   · 

  1 min read
• 

  Biotech Beach

  4 Solid Biotechs to Load Up on This Month

  Barring a huge meltdown, the S&P 500 will once again have a double-digit year of gains, and most investors should be looking at their 401(k)s and other accounts with some added holiday cheer.

  December 4, 2017

   · 

  1 min read